Inside the journey: A qualitative study of intravenous ketamine therapy for treatment-resistant depression
Journal of Affective Disorders Reports April 28, 2025 Jason Perepelkin, Polixeni Hantjidis, Kirsten Robison et al. 3 citations
Introduction: Treatment-resistant depression (TRD) affects over 30 % of patients with depression and is associated with high morbidity and mortality. Intravenous (IV) ketamine has shown rapid and robust antidepressant effects for TRD. However, limited data exist on long-term maintenance and patient experiences, especially in North America. This study aims to explore the lived experiences of...